Abiopharma

New Form 8-K - Arcturus Therapeutics Holdings Inc. Filed: 2025-08-11 AccNo: 0001193805-25-001175 Size: 275 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Standard BioTools Reports Second Quarter 2025 Financial Results

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

New Form 6-K - Evogene Ltd. Filed: 2025-08-11 AccNo: 0001178913-25-002750 Size: 9 KB

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

New Form 8-K - GYRE THERAPEUTICS, INC. Filed: 2025-08-11 AccNo: 0000950170-25-106525 Size: 681 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial …

New Form 6-K - XYLO TECHNOLOGIES LTD Filed: 2025-08-11 AccNo: 0001213900-25-074280 Size: 14 KB

MindMed Announces New Employee Inducement Grants

Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Xenon Reports Second Quarter 2025 Financial Results & Business Update